Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
E. M. Tinoco (Vila Nova de Gaia, Portugal), A. Gigante (Vila Nova de Gaia, Portugal), A. Fernandes (Matosinhos, Portugal), B. Cabrita (Matosinhos, Portugal), C. Santa (Vila Nova de Gaia, Portugal), I. Sucena (Vila Nova de Gaia, Portugal), S. Martins (Covilhã, Portugal), D. Machado (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal). Impact of mepolizumab in severe asthma with nasal polyps. 889

Member's Comments

No comment yet.

Related content which might interest you: Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017 Additive effect of Zafirlukast in combination with Mometason furoate in treatment of Nasal polyps in patients with mild persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Quality of life, clinical symptoms and nasal obstruction in patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 418s Year: 2003 Aspirin-induced urticaria/angioedema without respiratory symptoms in severe asthmatics with nasal polyposis Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002 Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Nasal mucosa biopsy in patients with severe bronchial asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 To assess the effects of combined nasal and inhaled corticosteroid in patients with asthma and persistent allergic rhinitis Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Perception of nocturnal nasal obstruction in chronic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 565s Year: 2005 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy of symbicort administration in patients with bronchial asthma Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Effects of formoterol-budesonide combination on residual eosinophilic inflammation in distal airway of patients with well-controlled moderate asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Effects of a 12-month course with omalizumab on nasal polyps and basement membrane in severe atopic asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010